(1998). a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell
(1999). A: Safety and antitumor activity of recombinant soluble Apo2 ligand.
(1997). Apoptosis by death factor. Cell
(1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell
(2007). Cognetti F: A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol
(2002). Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med
(1999). Dixit VM: Caspase activation: the induced-proximity model.
(1997). DW: Control of apoptosis by proteases. Adv Pharmacol
(2000). Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res
(2002). Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/ DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood
(2003). El-Deiry WS: Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol
(1993). GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res
(2000). Intracellular mechanisms of TRAIL and its role in cancer therapy.
(2007). Liu C: Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res
(2000). PH: Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res
(1999). Reed JC: IAP family proteins – suppressors of apoptosis. Genes Dev
(2001). RK: Intracellular mechanisms of TRAIL: apoptosis through mitochondrial- dependent and -independent pathways. Oncogene
(2004). RK: The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.
(1999). SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev
(2001). SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science
(2000). SJ: tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev
(2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell
(2005). Srivastava RK: Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate
(2004). Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat
(2001). Srivastava RK: Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
(2003). Srivastava RK: Involvement of Proapoptotic Molecules Bax and Bak in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Mitochondrial Disruption and Apoptosis: Differential Regulation of Cytochrome c and Smac/DIABLO Release. Cancer Res
(2003). Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res
(2000). Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med